-
LOCALLY SOURCED
To find and license promising
development candidates from
domestic biotech/pharma
companies and universities -
REGIONALLY FINANCED
To establish sources of financing
from regional investment
communities -
GLOBALLY DEVELOPED
To develop assets up to human
PoC(Proof of Concept) globally
Pipeline
We have initially focused on small molecular entities (SME) for the treatment of inflammatory and fibrotic diseases and are gradually expanding our interests to the immuno-oncology field with advanced modalities.
News
Bridge Biotherapeutics Joins JLABS @ Shanghai, China
Becomes a resident company of the newly opened incubation center for life science and biotechnology in the Asia-Pacific region Bridge Biotherapeutics Inc., a clinical-stage biotech company, which aims to develop novel therapeutics for areas with high unmet medical needs, announced that the company is a new resident of JLABS @ Shanghai in China, which opened on June 27th. Johnson & Johnson...
Read More-
LEARN MORE ABOUT US
-
CONTACT INFORMATION
HQ: Suite 903-2, Bldg B, Innovalley, 253 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486 Republic of Korea
US Office: Bridge Biotherapeutics, Inc. in JLABS@TMC, 2450 Holcombe Blvd. Houston, TX 77021, USADirector, Jong-jin Lim (jong-jin.lim@bridgebiorx.com)
Manager, Joengbin Ahn (Joengbin.ahn@bridgebiorx.com)